Monitor the vote on Proposal No. 1 requires two-thirds of all outstanding shares — any non-vote counts as a vote AGAINST — making turnout the key variable. If the activist Venrock (9.99% stake) may influence turnout or vote outcome.
Price Chart
Executive Summary
Korsana Biosciences is resubmitting a proposal to redomesticate from Massachusetts to the Cayman Islands at a special meeting on November 13, 2026, after a similar proposal failed at the August 2026 annual meeting received 61.8% of votes cast but failed due to low turnout. The board unanimously recommends voting FOR all three proposals, with Proposal No. 1 requires two-thirds of all outstanding shares, meaning any non-vote counts as a vote AGAINST. A recent SC 13D filed by Venrock Healthcare Capital Partners (9.99% stake) signals activist pressure ahead of this proxy statement.
Key Facts
- Special meeting on November 13, 2026 to approve redomestication from Massachusetts to the Cayman Islands
- Proposal No. 1 requires affirmative vote of not less than two-thirds of all shares entitled to vote on the matter
- Proposal No. 2 requires affirmative vote of not less than two-thirds of the votes properly cast
- Proposal No. 3 to approve adjournments if necessary to solicit additional proxies
- Venrock Healthcare Capital Partners filed SC 13D on September 15, 2026 (30d ago) — activist stake before proxy statement
- At the August 26, 2026 annual meeting the redomestication proposal received 61.8% of votes cast but failed due to low voter turnout
- The company has retained Innisfree M&A Incorporated as proxy solicitor in connection with the Special Meeting
- The Company expects to pay fees of Innisfree approximately $30,000
Financial Impact
No financial data in the filing; proxy solicitor fees expected to be approximately $30,000
Risk Factors
- Proposal No. 1 requires two-thirds of all shares entitled to vote — any non-vote counts as a vote AGAINST
- The redomestication proposal failed at the August 2026 annual meeting due to low voter turnout
- The Cayman Articles will introduce a classified board with staggered three-year terms and anti-takeover provisions
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001193125-26-422893 |
| Document: 0001193125-26-422893-index-headers.html | 0001193125-26-422893 |
| Document: 0001193125-26-422893-index.html | 0001193125-26-422893 |
| Document: 0001193125-26-422893.txt | 0001193125-26-422893 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 144 | $31.31 | awaiting T+20 | — | $31.60 (+0.93%) |
Oct 15, 2026 11d ago | SC 13G/A | $32.38 | awaiting T+20 | — | $31.60 (−2.41%) |
Oct 15, 2026 11d ago | DEF 14A | $32.38 | awaiting T+20 | — | $31.60 (−2.41%) |
Sep 23, 2026 4w ago | 144 | $37.19 $33.43 | ▼ −10.11% | ▼ −9.69% | $31.60 (−15.03%) |
Sep 22, 2026 4w ago | 144 | $32.30 $32.54 | ▲ +0.74% | ▲ +0.06% | $31.60 (−2.17%) |
Sep 18, 2026 5w ago | SC 13G | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $31.60 (−4.85%) |
Sep 18, 2026 5w ago | 144 | $33.21 $31.41 | ▼ −5.42% | ▼ −4.51% | $31.60 (−4.85%) |
Sep 16, 2026 5w ago | SC 13G | $31.23 $34.32 | ▲ +9.89% | ▲ +7.83% | $31.60 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers